ResearchMoz

Humalog (Type 2 Diabetes) - Analysis and Forecasts to 2020

GlobalData
Published Date » 2012-01-31
No. Of Pages » 44


GlobalDatas pharmaceuticals report, Humalog (Type 2 Diabetes) Analysis and Forecasts to 2020 provides Humalog sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Humalog including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Humalog including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2011-2020 for Humalog in each of the seven major markets
Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4

2 Introduction 5
2.1 Diabetes 5
2.2 Epidemiology 5
2.2.1 Prevalence 5
2.2.2 Mortality 7
2.3 Etiology and Risk Factors 9
2.3.1 Obesity 9
2.3.2 Sedentary Lifestyle 9
2.3.3 Family History and Genetics 9
2.3.4 Ethnicity 9
2.3.5 Old Age 9
2.4 Economic Impact of Diabetes 9
2.5 GlobalData Report Guidance 11

3 Type 2 Diabetes: Market Characterization 12
3.1 Type 2 Diabetes Market 12
3.2 Type 2 Diabetes Market Forecasts 13
3.3 Type 2 Diabetes Market: Drivers and Restraints 14
3.3.1 Drivers 14
3.3.2 Restraints 15

4 Classification of Diabetes 16
4.1 Types of Diabetes 16
4.1.1 Type 1 Diabetes 16
4.1.2 Type 2 Diabetes 16
4.1.3 Gestational Diabetes 16
4.2 Diabetes Complications 16
4.2.1 Cardiovascular Disease 16
4.2.2 Nephropathy 17
4.2.3 Neuropathy 17
4.2.4 Amputation 17
4.2.5 Retinopathy 17
5 Evolution of Anti-Diabetic Treatments 18

6 Medications 20
6.1 Insulin 20
6.2 Oral Medications 20
6.2.1 Sulfonylureas (SUR) 20
6.2.2 Biguanides (BGDs) 20
6.2.3 Alpha-Glucosidase Inhibitors (AGI) 22
6.2.4 Meglitinides 22
6.2.5 Thiazolidinediones (TZDs) 23
6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 24
6.2.7 Oral Combination Therapy 24
6.3 Other Injectionable Medications 25
6.3.1 Pramlintide 25
6.3.2 Exenatide 25
6.4 Market Share as per Classes in Type 2 Diabetes 25

7 Humalog (insulin lispro) 26
7.1 Introduction 26
7.2 Mechanism of Action 26
7.3 Clinical Studies 26
7.3.1 Safety & Efficacy Study in Humalog & Humulin R 26
7.3.2 Comparison of Means of Glycemic Parameters 27
7.3.3 Combination Therapy 27
7.4 Approval History of Humalog 28
7.5 Factors Affecting Sales of Humalog 28
7.5.1 Growing Insulin Market 28
7.5.2 First in Class 28
7.5.3 Advantage of Humalog over Regular Insulin 28
7.5.4 Prevention of Spiking Blood Sugar between Meals 28
7.5.5 Effective Treatment for Low Blood Sugar at Night 28
7.6 Drug Evaluation 29
7.6.1 Drug Risk Benefit Score 29
7.6.2 Intensity of Competition 30
7.7 Sales Estimates 30
7.7.1 Target Patient Pool for Humalog 30
7.7.2 Dosing 30
7.7.3 Market Penetration 31
7.7.4 Annual Cost of Therapy 31
7.7.5 Sales Projections of Humalog 32

8 Diabetes Market: Appendix 41
8.1 Market Definitions 41
8.2 List of Abberiviations 41
8.3 Research Methodology 41
8.3.1 Coverage 42
8.3.2 Secondary Research 42
8.3.3 Forecasting 42
8.3.4 Number of patients approved to take the drug 42
8.3.5 Net Penetration of Drug 43
8.3.6 Net Annual Dosing 43
8.3.7 Annual Cost of Therapy 43
8.4 Drug Sales Estimates Model 43
8.5 Contact Us 43
8.6 Disclaimer 44
8.7 Sources 44

List of Tables


Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 10
Table 4: Type 2 Diabetes, World, Major Marketed Drugs By Sales ($m), 2010 12
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III 13
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 14
Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 15
Table 8: Diabetes Drugs Evolution 19
Table 9: Type 2 Diabetes Mellitus Adults 26
Table 10: Comparison of Means of Glycemic Parameters at the end of Combined Treatment periods (3 months for each treatment) 27
Table 11: Results of a Two Month Study in which Humalog was added to Sulfonylurea therapy in Patients not adequately controlled on Sulfonylureas alone 27
Table 12: Approval of Humalog 28
Table 13: Drug Risk Benefit Score, Humalog 29
Table 14: Drug Risk Benefit Score, Humalog Mix 75/25 29
Table 15: Humalog, Annual Cost of Therapy in Type 2 Diabetes, Global, 2011 31
Table 16: Humalog Mix 75/25, Annual Cost of Therapy in Type 2 Diabetes, Global, 2011 31
Table 17: Humalog franchise, Annual Cost of Therapy in Type 2 Diabetes, Global, 2011 31
Table 18: Humalog, Type 2 Diabetes, Global, Sales Estimates ($m), 20022020 32
Table 19: Humalog, Type 2 Diabetes, The US, Sales Estimates ($m), 20022020 33
Table 20: Humalog, Type 2 Diabetes, The UK, Sales Estimates ($m), 20022020 34
Table 21: Humalog, Type 2 Diabetes, France, Sales Estimates ($m), 20022020 35
Table 22: Humalog, Type 2 Diabetes, Germany, Sales Estimates ($m), 20022020 36
Table 23: Humalog, Type 2 Diabetes, Italy, Sales Estimates ($m), 20022020 37
Table 24: Humalog, Type 2 Diabetes, Spain, Sales Estimates ($m), 20022020 38
Table 25: Humalog, Type 2 Diabetes, Japan, Sales Estimates ($m), 20022020 39

List of Figures


Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 6
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 6
Figure 3: Diabetes, World, Mortality, 2010 7
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 8
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 20102020 13
Figure 6: Mechanism of Action of Sulfonylureas 20
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 21
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 22
Figure 9: Mechanism of Action of Thiazolidinediones 23
Figure 10: Mechanism of Action of DPP IV Inhibitors 24
Figure 11: Type 2 Diabetes, Global, Market Share by Value, By Class (%), 2010 25
Figure 12: Humalog, Type 2 Diabetes, Global, Sales Estimates ($m), 2002-2020 32
Figure 13: Humalog, Type 2 Diabetes, The US, Sales Estimates ($m), 20022020 33
Figure 14: Humalog, Type 2 Diabetes, The UK, Sales Estimates ($m), 20022020 34
Figure 15: Humalog, Type 2 Diabetes, France, Sales Estimates ($m), 20022020 35
Figure 16: Humalog, Type 2 Diabetes, Germany, Sales Estimates ($m), 20022020 36
Figure 17: Humalog, Type 2 Diabetes, Italy, Sales Estimates ($m), 20022020 37
Figure 18: Humalog, Type 2 Diabetes, Spain, Sales Estimates ($m), 20022020 38
Figure 19: Humalog, Type 2 Diabetes, Japan, Sales Estimates ($m), 2002-2020 39
Figure 20: Humalog, Type 2 Diabetes, Sales Distribution by Country (%), 2020 40
Figure 21: Patients Approved for the Drug 43

Upcoming Reports:

Styrene-Butadiene-Styrene (SBS) Block Copolymer Market - Global Industry Size, Market Share, Trends Analysis, And Forecast, 2012 - 2018
By - Transparency Market Research
SBS (Styrene - Butadiene-Styrene) copolymer block is a homopolymer formed by a styrene and butadiene link. It can be used as a substitute to traditional vulcanized rubber, owing to its high elasticity and viscosity nature. SBS block copolymer is used as an adhesive, because of its tenacious abilities. The Styrene - Butadiene-Styrene block copolymer market could be segmented into two major categories: on the basis of types into: thermoplastic elastomers, polybutadiene rubber, styrene butadiene rubber, styrene butadiene styrene rubber and others, and on the basis of end users...
Poland: titanium dioxide market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the titanium dioxide market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the titanium dioxide market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate...
Urodynamics Equipment And Disposables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Urodynamics testing is used to evaluate the performance of the bladder, pelvic floor muscle and urethra, and also aid in the appropriate diagnosis of functional disorders affecting the same.  The two major aspects assessed during these studies are the bladder pressure and urinary flow rate. There are two major types of urodynamic studies carried out, namely, simple and multiple channel urodynamic studies. A simple urodynamic study includes post-void residual urine measurement, non-invasive uroflow study and single channel cystometrography. These tests are intended to assess the...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Select License type:

Share this report

Related News

High-sodium Diet Increases Risks of Cardiovascular Diseases in Type 2 Diabetics
Jul 24, 2014  
A new research has found relation between the amount of salt in diet of diabetics and their chances of suffering from cardiovascular diseases. The research has stated that diabetics who have a high-salt diet are on a higher risk of having a chronic heart disease as compared to the ones who eat less salt.  The study’s findings provide evidences that support the benefits of a...
Strides Arcolab Bags USFDA Approval for Transplant Drug
Jul 24, 2014  
Indian pharmaceutical company Strides Arcolab has received the approval of the USFDA to sell its transplant drug Tacrolimus in the US market. The capsule is an immune-suppressant that is used for preventing organ rejection that may occur in transplant surgeries of organs such as kidneys, heart or liver in some patients.  USFDA has allowed the sale of the tablets in 5 mg, 1 mg and 0.5...
Chinese manufacturing gauge gets a hike after months
Jul 24, 2014  
China manufacturing gauge has climbed to its 18-month high this month, which has boosted the government’s chance of meeting the target for economic growth set for 2014, by a percentage of 7.5. The Purchasing Managers Index (PMI) preliminary from Markit Economics and HSBC Holdings Plc was at 52.0 and its has topped the 51.0 median estimate. These numbers indicate an above 50 mark. The...
Paracetamol doesn’t speed recovery or reduce low back pain: Study
Jul 24, 2014  
Paracetamol, which has long since been prescribed as a painkiller for severe low back pain, is no better than placebo; findings of a recent study in Australia have shown. The trial that was published on Thursday found that the universally recommended painkiller neither speeds recovery nor reduces the pain. Paracetamol is merely acts as a placebo or dummy pills doing nothing to ease the...
Early Treatment to Cure HIV virus Might not be Effective
Jul 23, 2014  
According to a research study, the virus of AIDS, HIV has the capacity of creating invulnerable strongholds in the host’s body rapidly. This has dashed hopes of early treatment for the condition, which might have been helpful to cure the virus. In one case, a baby was thought to be cured with the new treatment after its birth, however, the virus emerged couple of years later. A...